- Home
- NRGV vs VSTM Comparison
NRGV vs VSTM Comparison
Compare NRGV & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- VSTM
- Stock Information
- Founded
- NRGV 2017
- VSTM 2010
- Country
- NRGV United States
- VSTM United States
- Employees
- NRGV N/A
- VSTM N/A
- Industry
- NRGV Industrial Machinery/Components
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- VSTM Health Care
- Exchange
- NRGV Nasdaq
- VSTM Nasdaq
- Market Cap
- NRGV 260.1M
- VSTM 263.5M
- IPO Year
- NRGV N/A
- VSTM 2012
- Fundamental
- Price
- NRGV $1.45
- VSTM $5.68
- Analyst Decision
- NRGV Hold
- VSTM Strong Buy
- Analyst Count
- NRGV 5
- VSTM 8
- Target Price
- NRGV $1.95
- VSTM $12.67
- AVG Volume (30 Days)
- NRGV 867.6K
- VSTM 837.6K
- Earning Date
- NRGV 03-11-2025
- VSTM 03-13-2025
- Dividend Yield
- NRGV N/A
- VSTM N/A
- EPS Growth
- NRGV N/A
- VSTM N/A
- EPS
- NRGV N/A
- VSTM N/A
- Revenue
- NRGV $130,964,000.00
- VSTM $10,000,000.00
- Revenue This Year
- NRGV N/A
- VSTM N/A
- Revenue Next Year
- NRGV $633.68
- VSTM $117.91
- P/E Ratio
- NRGV N/A
- VSTM N/A
- Revenue Growth
- NRGV N/A
- VSTM N/A
- 52 Week Low
- NRGV $0.78
- VSTM $2.10
- 52 Week High
- NRGV $2.70
- VSTM $13.82
- Technical
- Relative Strength Index (RSI)
- NRGV 34.38
- VSTM 49.67
- Support Level
- NRGV $1.56
- VSTM $5.48
- Resistance Level
- NRGV $1.69
- VSTM $6.17
- Average True Range (ATR)
- NRGV 0.11
- VSTM 0.32
- MACD
- NRGV -0.01
- VSTM -0.07
- Stochastic Oscillator
- NRGV 0.00
- VSTM 35.53
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.